ADARx Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ADARx Pharmaceuticals, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 153.1 times by its yearly operating cash. Higher than 98% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
153.1×Debt due within a year is covered 153.1 times by its yearly operating cash.
Higher than 98% of Healthcare companies in United States.
Cash Cushion Ratio
+25%Cash, after subtracting all debt, equals 25% of its market value (net cash).
Higher than 66% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
ADARx Pharmaceuticals, Inc. made a loss over the last year. ADARx Pharmaceuticals, Inc. owes $1.55 for every $1 it owns. ADARx Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossADARx Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-7.52ADARx Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$1.9 BThe total market value of all of ADARx Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 73% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeADARx Pharmaceuticals, Inc.'s net worth is negative ($251 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.55×ADARx Pharmaceuticals, Inc. owes $1.55 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Dividend yield
NoneADARx Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossADARx Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-2119.1%ADARx Pharmaceuticals, Inc. lost $2119 for every $100 of revenue.
Cash vs debt
Net cashADARx Pharmaceuticals, Inc. held $472 M more cash than debt (net cash) at Dec 2025.
Questions
How much does ADARx Pharmaceuticals, Inc. owe compared with what it owns?
ADARx Pharmaceuticals, Inc. owes $1.55 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Does ADARx Pharmaceuticals, Inc. pay a dividend?
No. ADARx Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.